Trial reportCardiovascular and interventional radiology2026
Genicular Artery Embolization Using Imipenem/Cilastatin vs. Microsphere for Knee Osteoarthritis (GAUCHO). 12-Month Clinical Results of a Single-blind Randomized Controlled Trial.
Trial report in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the safety and clinical outcomes of genicular artery embolization (GAE) performed with permanent microspheres (PM) and imipenem/cilastatin (I/C) in patients with mild-to-moderate knee osteoarthritis. MATERIALS AND
methodsIn this IRB-approved prospective, randomized, single-center, single-blind trial, 60 patients with mild-to-moderate knee osteoarthritis were allocated to GAE with I/C (n = 30) or microspheres (n = 30). Clinical outcomes were assessed at baseline, 30 days, 90 days, and 365 days using Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Knee Injury and Osteoarthritis Outcome Score (KOOS).
resultsBaseline characteristics were similar between groups, except for a higher rate of bilateral treatment in the microsphere group (56.6% vs. 30.0%, p = 0.037). Technical success was achieved in all procedures, with lower embolic volume in the microsphere group (p = 0.003). The mean volume of embolic was 1.5 ml in the microsphere group and 2.0 ml in the I/C group (p = 0.003). Between-group comparisons showed no significant differences in VAS at 30, 90, and 365 days (3.20 vs. 2.28, p = 0.102; 3.38 vs. 3.33, p = 0.931; and 3.95 vs. 3.88, p = 0.928), in WOMAC pain (6.25 vs. 4.83, p = 0.182; 8.11 vs. 6.00, p = 0.051; and 7.50 vs 6.27, p = 0.323), or in KOOS pain (63.59 vs. 72.12, p = 0.115; 56.58 vs. 67.14, p = 0.074; and 53.76 vs. 65.81, p = 0.081) for I/C versus microspheres, respectively.
conclusionGAE using either I/C or microspheres is safe and effective, with significant clinical improvement over 12 months and no major differences in adverse events and pain outcomes between embolic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.